Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

477

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

March 26, 2026

Conditions

MULTIPLE MYELOMA (MM)

Interventions

DRUG

Carfilzomib

DRUG

Cyclophosphamide

DRUG

Lenalidomide

DRUG

Dexamethasone

Trial Locations (1)

IRCCS--CROB --CROB di Rionero in di Rionero in Vulture, Rionero in Vulture

All Listed Sponsors

lead

Mario Boccadoro

OTHER